Skip to main content

Table 1 Baseline characteristics of patients

From: Does subcutaneous administration of recombinant human erythropoietin increase thrombotic events in total hip arthroplasty? A prospective thrombelastography analysis

 

rHu-EPO group

(n = 74)

Control group

(n = 78)

P value

Age (years)

66.2 ± 10.9

65.7 ± 9.1

0.773

Female sex

44(59.5%)

40(51.3%)

0.311

Weight (kg)

65.9 ± 7.3

65.5 ± 9.1

0.805

Body mass index (kg/m2)

23.8 ± 3.7

23.7 ± 3.6

0.958

Harris score

44.84 ± 11.87

43.53 ± 10.90

0.479

Comorbidity

   

 Hypertension

 Diabetes mellitus

39(52.7%)

3(4.1%)

45(57.7%)

9(11.5%)

0.625

0.132

  1. *P < 0.05